P1.13A.09 RYZ101 (225Ac-DOTATATE) + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor Expressing Extensive-Stage Small-Cell Lung Cancer
Sonam Puri(University of Utah), Z. Hao(Markey Cancer Center), Justin Rineer(Orlando Health), Jason Berilgen(Millennium Engineering and Integration (United States)), Wallace Akerley(University of Utah), Mathew L. Thakur, J. Goldman(University of California, Los Angeles), Jérémie Calais(University of California, Los Angeles), Claire K. Mulvey(University of California, San Francisco), Denis Gonçalves Ferreira, J. Li, Barbara Mancini(Spectrum Health), Kristen E. Howell(Texas A&M University), Éric Parent(University of Alberta), Sam Mehr(Children's Hospital at Westmead), Noridza Rivera-Rodríguez, Aaron S. Mansfield(Chinese University of Hong Kong), D. Bushnell(University of Iowa), Ye Yuan(Peking University), Ling Gong, N. Pascale, Robert M. Langdon(Sidney Kimmel Cancer Center)
Cited by 1
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2019|1k
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
|Journal of Clinical Oncology|2015|903